Objective: Despite recommendations that young people at clinical high risk (CHR) for psychosis receive stepped treatment, few programs have published details of their clinical models or outcomes. This study describes the preliminary effectiveness of a risk calculator-informed stepped care model used at the Yale PRIME Clinic, a specialized outpatient clinic for young people at CHR. Methods: Seventy-one individuals (ages 12-25) at CHR enrolled in Yale’s PRIME Clinic during the first four years of the treatment program. Participants completed clinical assessments at six timepoints over two years of treatment within a care model informed by an empirically grounded psychosis risk calculator. Linear mixed-effect models were fit to examine changes in clinical symptoms over time, and sensitivity analyses evaluated differences in clinical trajectories between completers and non-completers. Results: Individuals engaged in treatment demonstrated significant and sustained improvements in positive, negative, general, disorganized, and depressive symptoms. Improvements in positive symptoms emerged by 6 months and continued to improve across most subsequent timepoints (6, 12, and 24 months). Pattern mixture analyses suggested that clinical trajectories did not significantly differ between completers and non-completers, though non-completers possessed more heterogeneous trajectories. Conclusions: A stepped care model informed by individualized risk calculator scores was feasible for delivery in a specialized outpatient setting, and was associated with broad symptom improvement for young people at CHR. Further controlled studies with blinded raters are needed to further confirm the efficacy of stepped care models and isolate the active components of treatment. Highlights: Participants at clinical high risk for psychosis experienced significant reductions in attenuated psychotic symptoms and improvements in mood while enrolled in a risk-calculator-informed stepped care treatment model. Participants who disengaged from treatment did not have significantly different clinical trajectories than those who remained in care. The results suggest preliminary evidence for the feasibility of implementing a risk-calculator-informed stepped care model.
Objective: Cognitive models of psychosis implicate maladaptive core schemas in the development and emergence of psychotic symptoms, but no study has tested temporal dynamics between schemas and psychotic symptoms in a large sample of clinical high-risk (CHR) youth. Given their sizable role in cognitive behavioral therapies, the first-line treatment for CHR youth, core schemas may be key to both symptom development and treatment in this population. Methods: Participants were 578 CHR individuals from the second North American Prodrome Longitudinal Study (NAPLS-2) assessed across five timepoints. Time-lagged mixed-effects models tested forward (schema→outcome) and reverse (outcome→schema) paths for each Brief Core Schema Scales subscale with both psychotic symptom and functioning changes, controlling for autoregressive effects, time-varying depression, and linear time. Results: Twenty of 36 schema–outcome pairs showed significant prospective associations. Negative-other schemas were prospectively associated with worsening across nearly all psychosis symptom and functioning domains. Suspiciousness exhibited bidirectional associations with all four schema subscales. Grandiose ideas were uniquely prospectively associated with positive-self and negative-other schemas. Positive schemas were prospectively associated with decreases in suspiciousness, negative symptoms, and improvements in functioning. Effects were largely independent of depressive symptoms and robust across sensitivity analyses, with partial attenuation of self-schema effects on suspiciousness. Conclusions: Core schemas were prospectively associated with psychosis symptom and functioning change in CHR youth, with symptom-domain specificity and bidirectionality. These findings extend cognitive models of psychosis into CHR syndromes and highlight schemas as potentially modifiable treatment targets to improve outcomes in this population. Highlights: Schema changes preceded shifts in functioning and psychosis symptoms among CHR youth Negative-other schemas preceded worsening across nearly all outcome domains Suspiciousness was the only outcome with bidirectional schema associations Positive schemas preceded fewer negative symptoms and better global functioning
Aim: Core schemas are considered stable traits in clinical high risk (CHR) research. However, unexamined fluctuation may conceal belief changes that precede psychosis emergence. We examined whether schemas possess considerable within-person variability in CHR, and whether that variability exceeds that of controls. Methods: In NAPLS-2, 411 CHR and 194 control participants completed the Brief Core Schema Scales (BCSS) at least three times across 24 months. Random-intercept models identified intraclass correlations in CHR. Bayesian censored location-scale models, correcting for floor scores and mean level differences, compared within-person SD between groups. Results: Within-person variance accounted for 41.3%–50.6% of BCSS variance in CHR. Latent within-person SD was greater in CHR on all four subscales, most for negative-self (ratio 1.71, 95% CrI [1.50, 1.94]). This variability was largely independent of shared improvement and psychotropic medication effects. Conclusions: Core schemas fluctuate substantially in CHR compared to controls, particularly in negative self-beliefs. Single baseline scores may understate schema–outcome associations.